TCR2 Therapeutics (NASDAQ:TCRR) Downgraded to Neutral at HC Wainwright

HC Wainwright cut shares of TCR2 Therapeutics (NASDAQ:TCRR – Get Rating) from a buy rating to a neutral rating in a research report sent to investors on Tuesday, The Fly reports.

Several other research firms also recently weighed in on TCRR. Piper Sandler upped their price objective on shares of TCR2 Therapeutics from $8.00 to $10.00 and gave the stock an overweight rating in a report on Thursday, January 5th. EF Hutton Acquisition Co. I assumed coverage on shares of TCR2 Therapeutics in a report on Thursday, January 5th. They set a hold rating and a $2.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of Hold and an average price target of $10.75.

TCR2 Therapeutics Trading Down 1.2 %

TCRR opened at $1.60 on Tuesday. The company’s fifty day moving average price is $1.26 and its two-hundred day moving average price is $1.55. TCR2 Therapeutics has a 1-year low of $0.82 and a 1-year high of $3.88. The company has a market cap of $61.86 million, a price-to-earnings ratio of -0.52 and a beta of 1.90.

Institutional Trading of TCR2 Therapeutics

Several institutional investors have recently made changes to their positions in the company. Jane Street Group LLC grew its stake in shares of TCR2 Therapeutics by 162.3% in the 4th quarter. Jane Street Group LLC now owns 41,295 shares of the company’s stock worth $41,000 after acquiring an additional 25,553 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of TCR2 Therapeutics by 43.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 48,900 shares of the company’s stock worth $49,000 after acquiring an additional 14,700 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of TCR2 Therapeutics by 161.3% in the 4th quarter. Wells Fargo & Company MN now owns 26,684 shares of the company’s stock worth $27,000 after acquiring an additional 16,471 shares in the last quarter. Citigroup Inc. grew its stake in shares of TCR2 Therapeutics by 103,055.6% in the 4th quarter. Citigroup Inc. now owns 473,484 shares of the company’s stock worth $473,000 after acquiring an additional 473,025 shares in the last quarter. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of TCR2 Therapeutics in the 3rd quarter worth $34,000. Institutional investors own 64.76% of the company’s stock.

TCR2 Therapeutics Company Profile

(Get Rating)

TCR2 Therapeutics, Inc is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development.